Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 8, 2011, Pages 711-715

  Floreani, Annarosa ^a   Cazzagon, Nora ^a   Furlan, Patrizia ^a   Baldovin, Tatjana ^a   Egoue, Joel ^a   Antoniazzi, Sara ^a   Baldo, Vincenzo ^a   Minola, Eliseo ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Bergamo Hospital   (Italy)

Author keywords

antiviral therapy; genotypes; hepatitis C virus; relapsers; retreatment

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETREATMENT;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RETREATMENT; RIBAVIRIN; TREATMENT OUTCOME;

EID: 79960698392     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834846ff     Document Type: Article

References (20)

1. Ghany MG, Strader DB, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
2. Mangia A, Andriulli A. Tailoring the length of antiviral treatment of hepatitis C. Gut 2010; 59:1-5.
3. Heathcote J. Retreatment of chronic hepatitis C: who and how? Liver Int 2009; 29 (s1):49-56.
4. Sherman KE, Fleisher R, Laessig K, Murray J, Tauber W, Birnkrant D, et al. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 2007; 46:2014-2020.
5. Berg C, Concales FL Jr, Bernstein DE, Sette H Jr, Rasenack J, Diago M. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepatitis 2006; 13:435-440.
6. Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, et al. Peginterferon alfa-2a (40 kDa) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 2006; 10:11-16. (Pubitemid 43881087)
7. Krawitt EL, Ashikaga T, Gondon SR, Ferrentino N, Ray MA, Lidofsky SD, et al. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43:243-249. (Pubitemid 40956876)
8. Jacobson IM, Gonzales SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC, et al. A randomized trial of pegylated interferon a-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005; 100:2453-2462.
9. Herrine SK, Brown RS Jr, Bernstein DE, Ondovik MS, Lentz E, Te H. Peginterferon a-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon a-2b plus ribavirin: a pilot study of efficacy and safety. Dig Dis Sci 2005; 50:719-726. (Pubitemid 40558467)
10. Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136:1618-1628.
11. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, et al. Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006; 55:1631-1638. (Pubitemid 44629215)
12. Kaiser S, Lutze B, Hass HG, Werner CR. High sustained virological response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2A (40 KD) plus ribavirin for 72 weeks (Abst 1860). Hepatology 2008; 48 (Suppl 4):1140A.
13. EASL International Consensus Conference on Hepatitis C Paris 26-27 February 1999. Consensus Statement. J Hepatol 1999; 31:S3-S8.
14. Berg T, Von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 vs. 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
15. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R. Randomized study of peginterferon-alpha2a plus ribavirin vs. peginterferonalpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010; 138:108-115.
16. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-122.
17. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
18. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011; 54:439-448.
19. Morgan TR, O'Brien TR. IL28B genotype testing now and in the era of direct-acting antiviral agents. Clin Gastroenterol Hepatol 2011; 9:293-294.
20. Mangia A. IL28B: a new wager in the skyline of hepatitis C virus infection. Dig Liver Dis 2011; 43:177-179.